Using Tenecteplase after Mechanical Thrombectomy for Stroke
Official title: Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial
Run by ProMedica Health System · NCT06949228 · Data updated 2026-11-12
This study is testing if adding a drug called Tenecteplase after a procedure to remove a blood clot can help people who have had a stroke feel better and recover more effectively.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 132 (estimated) |
| Sponsor | ProMedica Health System Academic / other |
| Locations | 1 site (Toledo, Ohio) |
| Status | Recruiting |
| Started | July 30, 2025 |
| Main results expected | May 30, 2028 |
| Study ends | May 30, 2028 |
| Registry record updated | January 21, 2026 |
| Trial ID | NCT06949228 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-85 who have experienced an anterior circulation ischemic stroke and have undergone mechanical thrombectomy.
✕Probably not a fit
Patients with significant premorbid disability, active hemorrhagic conditions, or those on certain anticoagulant therapies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial evaluates the safety and effectiveness of intra-arterial Tenecteplase as an additional treatment for patients experiencing acute ischemic stroke due to large vessel occlusions. Participants must have undergone mechanical thrombectomy and achieved a specific level of blood flow restoration. The study focuses on patients with anterior circulation strokes and aims to determine if this adjunctive therapy can improve outcomes following thrombectomy. The trial is conducted at ProMedica Toledo Hospital in Ohio.
Why it matters
Potential benefit: If successful, this treatment could significantly improve recovery outcomes for patients suffering from acute ischemic strokes.
How similar studies have gone: Other studies have shown promise with similar thrombolytic approaches, suggesting potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18-85 2. Anterior circulation ischemic stroke symptoms with confirmed occlusion (ICA, M1, or M2) on angiogram and mechanical thrombectomy initiated within 24 hours since last known well 3. Alberta Stroke Program Early CT Score (ASPECTS) Score ≥6 on baseline Non-contrast Head CT (NCCT) 4. Post-mechanical thrombectomy with ≤5 device passes and mTICI grade 2b or higher. 5. Ability to obtain signed informed consent prior to randomization from LAR or Subject Exclusion Criteria: 1. Premorbid modified Rankin scale (mRS) score \>1 2. Imaging evidence of hemorrhage or mass effect at baseline 3. Platelet count \<100,000 4. Active hemorrhagic diathesis, or known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency 5. Active anticoagulation treatment with novel oral anticoagulant (NOACs) taken within the last 48 hours, or INR \>1.7 6. Patients requiring active treatment with dual antiplatelet agents (e.g. proximal cervical carotid artery stenting) 7. Pregnant or lactating 8. Previous known allergy to TNK 9. Major surgery in past 30 days 10. Patient is on or requires dialysis 11. History of intracranial hemorrhage or serious head trauma at any time 12. Any condition in the opinion of the enrolling physician that would preclude the patient from participating 13. Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluation 14. Severe, uncontrolled hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg) that is refractory to treatment 15. History of acute ischemic stroke in the last 60 days and/or has received previous treatment with a thrombolytic within the last 90 days 16. Presumed septic embolus; suspicion of bacterial endocarditis 17. Suspicion of aortic dissection 18. Intracranial neoplasm 19. Any terminal medical condition with life expectancy less than 6 months 20. Concurrent enrollment in another trial that could confound the results of this study 21. Patient is unlikely to return for 90-day follow-up. 22. Intravenous tissue plasminogen activator (tPA) administered concurrently with Intra-arterial TNK
Where it's running
-
ProMedica Toledo Hospital
Toledo, Ohio, United States Recruiting
Study contacts
- Study coordinator: Syed Fazal Zaidi, MD
- Email: Syed.Zaidi2@utoledo.edu
- Phone: (419)- 291-8027
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Remote ischemic conditioning for post-stroke insomnia
A 136-person, randomized study will test whether a non-invasive arm-cuff procedure done twice daily for 90 days can improve sleep after a first ischemic stroke in adults 18–80.
-
Ear-based nerve stimulation to help sleep after a stroke
A device that delivers vagal nerve stimulation through the ear is tested to see if it helps stroke patients in rehab sleep better.
-
Theta Burst Stimulation to Help Stroke Recovery (Upper and Lower Limbs)
This trial tests whether applying theta burst stimulation to the motor cortex, in combination with standard rehabilitation, helps people over 45 who recently had a first ischemic stroke recover arm and leg movement.
-
Preventing another ischemic stroke with a smart bracelet and app
This study tests whether a digital prevention program using a wearable and a mobile app can help people who recently had an ischemic stroke reduce the chance of another stroke and improve risk-factor control.
-
Photon-counting CT to check intracranial stents
This study tests whether ultra-high-resolution photon-counting CT can reliably visualize intracranial stents and detect in-stent restenosis during follow-up of patients with prior stents.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.